A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-233 SR For Relief of Vasomotor Symptoms Associated With Menopause

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-233 SR For Relief of Vasomotor Symptoms Associated With Menopause

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2008

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Menopause; Vasomotor symptoms
  • Focus Therapeutic Use
  • Sponsors Wyeth
  • Most Recent Events

    • 17 Oct 2007 Results presented at ASRM 2007.
    • 09 May 2007 Results have been published.
    • 10 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top